Información del artículo
El Texto completo está disponible en PDF
References
[1.]
P. Anagnostis, V.G. Athyros, C. Tziomalos, A. Karagiannis, D.P. Mikhilidis.
The pathogenetic role of cortisol in the metabolic syndrome: A hypothesis.
J Clin Endocrinol Metab, 94 (2009), pp. 2692-2701
[2.]
M.S. Cooper, P.M. Stewart.
11β-Hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome and inflammation.
J Clin Endocrinol Metab, 94 (2009), pp. 4645-4654
[3.]
R. Basu, D.S. Edgerton, R.J. Singh, A. Cherrington, R.A. RIzza.
Splanchnic cortisol production in dogs occurs primarily in the liver. Evidence for substantial hepatic specific 11β-Hydroxysteroid dehydrogenase type 1 activity.
Diabetes, 55 (2006), pp. 3013-3019
[4.]
R. Basu, A. Basu, M. Grudzien, P. Jung, P. Jacobson, M. Johnson, et al.
The liver is the site of splanchnic cortisol production in obese nondiabetic humans.
Diabetes, 58 (2009), pp. 39-45
[5.]
N. Draper, P.M. Stewart.
11β-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
J Endocrinol, 186 (2005), pp. 251-271
[6.]
C. Monder, P.C. White.
11β-Hydroxysteroid dehydrogenase.
Vit Horm, 47 (1993), pp. 187-271
[7.]
M.L. Ricketts, J.M. Verhaeg, I. Bujalska, A.J. Howie, W.E. Rainey, P.M. Stewart.
Immunohistochemical localization of type 1 11β-Hydroxysteroid dehydrogenase in human tissues.
J Clin Endocrinol Metab, 83 (1998), pp. 1325-1335
[8.]
G.M. Tannin, A.K. Agarwal, C. Monder, M.I. New, P.C. White.
The human gene for 11β-Hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization.
J Biol Chem, 266 (1991), pp. 16653-16658
[9.]
N.M. Morton.
Obesity and corticosteroids: 11β-Hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
Mol Cell Endocrinol, 316 (2010), pp. 154-164
[10.]
G.C. Lavery, E.A. Walker, N. Draper, P. Jeyasuria, J. Marcos, C.H. Shackleton, et al.
Hexose-6-phosphate dehydrogenase knock out mice lack 11β-Hydroxysteroid dehydrogenase type-1 mediated glucocorticoid generation.
J Biol Chem, 281 (2006), pp. 6546-6551
[11.]
A. Odermatt, A.G. Atanasov, Z. Balazs, R.A.S. Schweizer, L.G. Nashev, D. Schuster, et al.
Why is 11β-Hydroxysteroid dehydrogenase type-1 facing the endoplasmic reticulum lumen? Physiological relevance of the membrane topology of 11β-HSD1.
Mol Cell Endocrinol, 248 (2006), pp. 15-23
[12.]
P.W.F. Hadoke, J. Iqbal, B.R. Walker.
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.
Br J Pharmacol, 156 (2009), pp. 689-912
[13.]
J.M. Paterson, J.R. Seckl, J.J. Mullins.
Genetic manipulation of 11β-Hydroxysteroid dehydrogenases in mice.
Am J Physiol Regul Integr Comp Physiol, 289 (2005), pp. R642-R652
[14.]
J. Rosenstock, S. Banarer, V.A. Fonseca, S.E. Inzucchi, W. Sun, W. Yao, et al.
The 11β-Hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.
Diabetes Care, 33 (2010), pp. 1516-1522
[15.]
P.M. Stewart, A. Boulton, S. Kumar, P.M.S. Clark, C.H.L. Shackleton.
Cortisol metabolism in human obesity: impired cortisone→cortisol conversion in subjects with central adiposity.
J Clin Endocrinol Metab, 84 (1999), pp. 1022-1027
[16.]
E. Rask, T. Olsson, S. Söderberg, R. Andrew, D.E. Livingstone, O. Johnson, et al.
Tissue-specific dysregulation of cortisol metabolism in human obesity.
J Clin Endocrinol Metab, 86 (2001), pp. 1418-1421
[17.]
E. Rask, B.R. Walker, S. Söderberg, D.E. Livingstone, M. Eliasson, O. Johnson, et al.
Tissue-specific changes in peripheral cortisol metabolism in obese women: Increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity.
J Clin Endocrinol Metab, 87 (2002), pp. 3330-3336
[18.]
G. Valmasakis, A. Anwar, J.W. Tomlinson, C.H.L. Shackleton, P.G. McTernan, R. Chetty, et al.
11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus.
J Clin Endocrinol Metab, 89 (2004), pp. 4755-4761
[19.]
J.W. Tomlinson, J.S. Moore, P.M.S. Clark, G. Holder, L. Shakespeare, P.M. Stewart.
Weight loss increases 11β-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue.
J Clin Endocrinol Metab, 89 (2004), pp. 2711-2716
[20.]
J. Westerbacka, Yki-Järvinen, S. Vehkavaara, A.-M. Häkkinen, R. Andrew, D.J. Wake, et al.
Body fat distribution and cortisol metabolism in Healthy men: enhanced 5β-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver.
J Clin Endocrinol Metab, 88 (2003), pp. 4924-4931
[21.]
R. Desbrière, V. Vuaroqueaux, V. Achard, S. Boullu-Ciocca, M. Labuhn, A. Dutour, et al.
11β-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.
Obesity, 14 (2006), pp. 794-798
[22.]
B. Mariniello, V. Ronconi, S. Rilli, P. Bernante, M. Boscaro, F. Mantero, et al.
Adipose tissue 11β-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing syndrome.
J Endocrinol, 155 (2006), pp. 435-441
[23.]
A. Veilleux, C. Rhéaume, M. Daris, V. Luu-The, A. Tchernof.
Omental adipose tissue type 1 11β-hydroxysteroid dehydrogenase oxoreductase activity, body fat distribution, and metabolic alterations in women.
J Clin Endocrinol Metab, 94 (2009), pp. 3550-3557
[24.]
J.W. Tomlinson, B. Sinha, I. Bujalska, M. Hewison, P.M. Stewart.
Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity.
J Clin Endocrinol Metab, 87 (2002), pp. 5630-5635
[25.]
G. ÜçKaya, N. Karadurmus, O. Kutlu, A. Çorakçi, S. Kizildag, A.U. Ural, et al.
Adipose tissue 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase gene expressions are increased in patients with type 2 diabetes mellitus.
Diabetes Res Clin Practice, 82S (2008), pp. S135-S140
[26.]
R. Muñoz, C. Carvajal, A. Escalona, C. Boza, G. Pérez, L. Ibáñez.
11β-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients.
Obes Surg, 19 (2009), pp. 764-770
[27.]
O. Paulmyer-Lacroix, S. Boullu, Ch Oliver, M.-C. Alessi, M. Grino.
Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: An in situ hybridization study.
J Clin Endocrinol Metab, 87 (2002), pp. 2701-2705
[28.]
K. Kannisto, K.H. Pietiläinen, E. Ehrenborg, A. Rissanen, J. Kaprio, A. Hamsten, et al.
Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins.
J Clin Endocrinol Metab, 89 (2004), pp. 4414-4421
[29.]
S. Engeli, J. Böhnke, M. Feldpausch, K. Gorzelniak, U. Heintze, F. Luftn, et al.
Regulation of 11β-HSD genes in human adipose tissue: influence of central obesity and weight loss.
Obes Res, 12 (2004), pp. 9-17
[30.]
R.S. Lindsay, D.J. Wake, S. Nair, J. Bunt, D.E.W. Livingstone, P.A. Permana, et al.
Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima indians and caucasians.
J Clin Endocrinol Metab, 88 (2003), pp. 2738-2744
[31.]
T.C. Sandeep, R. Andrew, N.Z.M. Homer, R.C. Andrews, K. Smith, B.R. Walker.
Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Diabetes, 54 (2005), pp. 872-879
[32.]
J. Koska, B. Courten, D.J. Wake, S. Nair, B.R. Walker, J.C. Bunt.
11β-hydroxysteroid dehydrogenase type 1 in adipose tissue and prospective changes in body weight and insulin resistance.
Obesity, 14 (2006), pp. 1515-1522
[33.]
J.W. Tomlinson, J. Finney, G. Gay, B.A. Hughes, S.V. Hughes, P.M. Stewart.
Impaired glucose tolerance and insulin resistance are associated with increased adipose 11β-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5α-reductase activity.
Diabetes, 57 (2008), pp. 2652-2660
[34.]
B.M. Abdallah, H. Beck-Nielsen, M. Gaster.
Increased expression of 11β-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes.
Eur J Clin Invest, 35 (2005), pp. 627-634
[35.]
E. Torrecilla, G. Fernández Vázquez, D. Vicent, A. Barabash, L. Cabrerizo, A. Sánchez Pernaute, et al.
Expresión de de 11β-hidroxiesteroide dehidrogenasa tipo1 y del receptor glucocorticoide en tejido hepático y adiposo (visceral y subcutáneo) en pacientes con obesidad mórbida, con y sin síndrome metabólico. Abstracts VIII Congreso de la Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad de Madrid (SENDIMAD).
Endocrinol Nutr, 56 (2009),
[36.]
D.S. Edgerton, R. Basu, C.J. Ramnanan, T.D. Farmer, D. Neal, M. Scott, et al.
Effect of 11β-Hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dogs.
Am J Physiol Endocrinol Metab, 298 (2010), pp. E1019-E1026
[37.]
Y. Iwasaki, S. Takayasu, M. Nishiyama, M. Tsugita, T. Taguchi, M. Asai, et al.
Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11β-Hydroxysteroid dehydrogenase-1) gene.
Mol Cell Endocrinol, 285 (2008), pp. 10-18
Copyright © 2011. Sociedad Española de Endocrinología y Nutrición
